BNT329

BNT329 is an investigational antibody-drug conjugate (ADC) developed by BioNTech. It targets carbohydrate antigen 19-9 (CA19-9, also known as sialyl-Lewis A), a tumor-associated antigen commonly expressed in gastrointestinal cancers, particularly pancreatic ductal adenocarcinoma, as well as bile duct, colorectal, gastroesophageal junction, endometrial, ovarian, and urothelial carcinomas. The monoclonal antibody component recognizes and binds CA19-9 on the tumor cell surface and is conjugated to the cytotoxic payload YL0010014, a topoisomerase 1 inhibitor, via a MediLink Tmalin linker-payload technology. The ADC is designed to selectively deliver the cytotoxic agent to CA19-9 expressing tumor cells, causing cell death and tumor regression. The drug is in early-phase clinical investigation for advanced solid tumors that express CA19-9, particularly those that have progressed after previous therapies[1][3][6].

Other names

CA19-9-targeting monoclonal antibodyCA-19-9-targeting monoclonal antibodyCA 19-9-targeting monoclonal antibodyCA19-9-targeting antibody-drug conjugateCA-19-9-targeting antibody-drug conjugateCA 19-9-targeting antibody-drug conjugateBNT329-ADCBNT-329-ADCBNT 329-ADC